|
KMID : 1148920080420000001
|
|
Nuclear Medicine and Molecular Imaging
2008 Volume.42 No. 0 p.1 ~ p.5
|
|
|
Clinical Application of 18F-FDG PET in Brain Tumors
|
|
Hong Il-Ki
Kim Jae-Seung
|
|
|
Abstract
|
|
|
|
Primary brain tumor accounts for 1.4% of entire cancer. For males between the ages of 15 and 34 years, central nervous system tumors account for the leading cause of cancer death. 18F-FDG PET has been reported that it can provide important diagnostic information relating to tumor grading and differentiation from non- tumorous condition. In addition, the degree of FDG metabolism carries prognostic significance. By mapping the metabolic pattern of heterogeneous tumors, 18F-FDG PET can aid in targeting for stereotactic biopsy by selecting the subregions within the tumor that are most hypermetabolic and potentially have the highest grade. According to clinical research data, FDG PET is expected to be a helpful diagnostic tool in the management of brain tumors. (Nucl Med Mol Imaging 2008;42(suppl 1):1-5)
|
|
|
KEYWORD
|
|
|
brain neoplasm, 18F-FDG, positron emission tomography
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|